Breaking Down Chemours: 8 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Chemours (NYSE:CC), with recent ratings showing a shift towards more conservative price targets. The average 12-month price target has decreased by 14.41% to $25.25. Chemours faces challenges with a 6.39% revenue decline but maintains strong profitability metrics.
October 11, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Chemours (NYSE:CC) has received mixed analyst ratings, with a notable decrease in the average 12-month price target by 14.41% to $25.25. Despite a 6.39% decline in revenue, the company shows strong profitability metrics.
The decrease in the average price target and the revenue decline suggest a negative short-term outlook. However, strong profitability metrics provide some support, leading to a slightly negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100